Quynh-thu X. Le

Quynh-thu X. Le's AcademicInfluence.com Rankings

Quynh-thu X. Le

Biology

#9574

World Rank

#12796

Historical Rank

Ecology

#529

World Rank

#581

Historical Rank

Molecular Biology

#1327

World Rank

#1354

Historical Rank

Biochemistry

#1474

World Rank

#1600

Historical Rank

biology Degrees

Download Badge

Biology

Quynh-thu X. Le's Degrees

PhD Biochemistry Stanford University
Bachelors Biochemistry University of California, Berkeley

Why Is Quynh-thu X. Le Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Quynh-thu X. Le's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Lysyl oxidase is essential for hypoxia-induced metastasis (2006) (1343)
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. (2009) (1081)
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. (2008) (1030)
Non-small cell lung cancer clinical practice guidelines in oncology. (2006) (1010)
Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial (2019) (716)
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. (2010) (692)
Nasopharyngeal carcinoma. (2019) (584)
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. (2009) (571)
Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. (2014) (521)
Pancreatic tumors show high levels of hypoxia. (2000) (493)
Hypoxic gene expression and metastasis (2004) (427)
Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. (2004) (404)
Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma. (2014) (400)
Candidate genes for the hypoxic tumor phenotype. (2000) (344)
Image-guided Hypo-fractionated Stereotactic Radiosurgery to Spinal Lesions (2001) (339)
MiR-210--micromanager of the hypoxia pathway. (2010) (334)
Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. (2014) (332)
The changing therapeutic landscape of head and neck cancer (2019) (327)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC) (2019) (327)
XBP1 Is Essential for Survival under Hypoxic Conditions and Is Required for Tumor Growth (2004) (320)
Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. (2003) (311)
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. (2005) (303)
p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. (2014) (300)
Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. (2010) (291)
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. (2004) (281)
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. (2012) (269)
An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers (2006) (261)
MYB Expression and Translocation in Adenoid Cystic Carcinomas and Other Salivary Gland Tumors With Clinicopathologic Correlation (2011) (237)
Galectin-1: a link between tumor hypoxia and tumor immune privilege. (2005) (231)
Proposal for the 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy (2016) (230)
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. (2009) (226)
Sample classification from protein mass spectrometry, by 'peak probability contrasts' (2004) (222)
Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors (2006) (221)
Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. (1997) (221)
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. (2003) (219)
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose (2008) (214)
Institutional clinical trial accrual volume and survival of patients with head and neck cancer. (2015) (206)
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. (2008) (200)
Metabolic tumor burden predicts for disease progression and death in lung cancer. (2007) (191)
Optimization of importance factors in inverse planning. (1999) (184)
International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. (2017) (175)
Role of beam orientation optimization in intensity-modulated radiation therapy. (2001) (172)
Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2017) (168)
Patterns of patient movement during frameless image-guided radiosurgery. (2003) (163)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy (2019) (162)
Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. (2011) (155)
Improved local control with stereotactic radiosurgical boost in patients with nasopharyngeal carcinoma. (2002) (147)
The effectiveness of breath-holding to stabilize lung and pancreas tumors during radiosurgery. (2002) (145)
Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement (2020) (143)
Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. (2006) (137)
Positron‐Emission Tomography for Surveillance of Head and Neck Cancer (2005) (135)
An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma (2013) (134)
Lymph node metastasis in maxillary sinus carcinoma. (2000) (133)
Identification of Mitogen-Activated Protein Kinase Signaling Pathways That Confer Resistance to Endoplasmic Reticulum Stress in Saccharomyces cerevisiae (2005) (129)
Future cancer research priorities in the USA: a Lancet Oncology Commission. (2017) (125)
Cell cycle proteins and the development of oral squamous cell carcinoma. (1999) (124)
PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models (2009) (120)
Primary radiotherapy for localized orbital MALT lymphoma. (2002) (120)
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. (2007) (117)
Mucositis-related morbidity and resource utilization in head and neck cancer patients receiving radiation therapy with or without chemotherapy. (2009) (117)
The tumor microenvironment in non-small-cell lung cancer. (2010) (116)
Tumor galectin-1 mediates tumor growth and metastasis through regulation of T-cell apoptosis. (2011) (114)
Phase II double-blind randomized study comparing oral aloe vera versus placebo to prevent radiation-related mucositis in patients with head-and-neck neoplasms. (2004) (112)
Prognostic nomogram for refining the prognostication of the proposed 8th edition of the AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity‐modulated radiotherapy (2016) (111)
Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer. (2017) (108)
Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy. (2016) (107)
Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. (2007) (106)
Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: clinical outcomes and patterns of failure. (2010) (105)
Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. (2010) (104)
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002) (2021) (103)
Non-small cell lung cancer. (2010) (103)
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. (2011) (103)
Prognostic factors in adult soft-tissue sarcomas of the head and neck. (1997) (102)
Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism (2018) (102)
Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer (2015) (101)
X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas. (2009) (97)
Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file. (2008) (97)
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. (2021) (96)
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. (2008) (95)
Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma. (2013) (94)
A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma (2005) (94)
Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. (2001) (93)
Treatment of maxillary sinus carcinoma (1999) (93)
A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies. (2018) (92)
Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer. (2012) (91)
Neurotrophic factor GDNF promotes survival of salivary stem cells. (2014) (90)
Dosimetric effects of patient displacement and collimator and gantry angle misalignment on intensity modulated radiation therapy. (2000) (90)
Longitudinal evaluation of the oral mucositis weekly questionnaire‐head and neck cancer, a patient‐reported outcomes questionnaire (2007) (90)
Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence (2013) (87)
Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma (2010) (86)
Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics (2010) (85)
Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinoma (2007) (85)
Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. (2012) (84)
Excellent local control with stereotactic radiotherapy boost after external beam radiotherapy in patients with nasopharyngeal carcinoma. (2008) (84)
Radiation therapy for intracranial germ cell tumors. (2003) (84)
Patterns of care in palliative radiotherapy: a population-based study. (2013) (83)
The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers (2004) (81)
A unifying probabilistic Bayesian approach to derive electron density from MRI for radiation therapy treatment planning (2014) (81)
Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer (2005) (79)
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. (2009) (79)
Stereotactic Ablative Radiotherapy for Reirradiation of Locally Recurrent Lung Tumors (2012) (79)
Current State of PCR-Based Epstein-Barr Virus DNA Testing for Nasopharyngeal Cancer. (2017) (77)
A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer. (2014) (77)
Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. (2018) (76)
Head and Neck Cancer in Cardiothoracic Transplant Recipients (2000) (75)
Apoptosis-associated proteins and the development of oral squamous cell carcinoma. (1999) (75)
Postoperative irradiation of minor salivary gland malignancies of the head and neck. (1999) (74)
Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. (2019) (74)
Clinical biomarkers for hypoxia targeting (2008) (72)
Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. (2010) (71)
International Guideline on Dose Prioritization and Acceptance Criteria in Radiotherapy Planning for Nasopharyngeal Carcinoma. (2019) (70)
Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. (2013) (69)
Intensity-modulated radiotherapy for oral cavity squamous cell carcinoma: patterns of failure and predictors of local control. (2011) (67)
Dose reconstruction for volumetric modulated arc therapy (VMAT) using cone-beam CT and dynamic log files (2010) (65)
Postradiation metabolic tumor volume predicts outcome in head-and-neck cancer. (2011) (65)
Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients. (2017) (64)
Image-guided radiosurgery in the treatment of spinal metastases. (2001) (64)
Neurotrophic Factors and Their Potential Applications in Tissue Regeneration (2016) (63)
Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. (2015) (63)
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234) (2016) (63)
Expression of the Human Copper Influx Transporter 1 in Normal and Malignant Human Tissues (2006) (61)
Plasma osteopontin is an independent prognostic marker for head and neck cancers. (2006) (59)
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. (2015) (59)
Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. (2002) (59)
Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. (2010) (58)
Estimation theory and model parameter selection for therapeutic treatment plan optimization. (1999) (58)
Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement (2020) (57)
CD271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma (2014) (57)
A Novel Aldehyde Dehydrogenase-3 Activator Leads to Adult Salivary Stem Cell Enrichment In Vivo (2011) (57)
The RGD Domain of Human Osteopontin Promotes Tumor Growth and Metastasis through Activation of Survival Pathways (2010) (57)
Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (55)
Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response (2014) (54)
Mature results from a randomized Phase II trial of cisplatin plus 5‐fluorouracil and radiotherapy with or without tirapazamine in patients with resectable Stage IV head and neck squamous cell carcinomas (2006) (54)
Understanding High-Dose, Ultra-High Dose-Rate and , Spatially Fractionated Radiotherapy. (2020) (53)
Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. (2015) (52)
Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis (2009) (52)
Chemical Space Mimicry for Drug Discovery (2017) (52)
Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. (2009) (52)
SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells (2017) (51)
Prognostic value of metabolic tumor volume and velocity in predicting head-and-neck cancer outcomes. (2010) (51)
Linac-based on-board imaging feasibility and the dosimetric consequences of head roll in head-and-neck IMRT plans. (2008) (51)
Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer. (2003) (50)
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. (2010) (50)
Head and neck cancer‐specific survival based on socioeconomic status in Asians and Pacific Islanders (2011) (50)
Quantification of motion of different thoracic locations using four-dimensional computed tomography: implications for radiotherapy planning. (2007) (49)
Human papillomavirus 16 detected in nasopharyngeal carcinomas in white Americans but not in endemic Southern Chinese patients (2014) (49)
Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. (2019) (49)
De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies (2020) (48)
Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial (2011) (47)
Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. (2012) (46)
Nuclear repartitioning of galectin-1 by an extracellular glycan switch regulates mammary morphogenesis (2016) (46)
Adult medulloblastoma: an analysis of survival and prognostic factors. (1997) (46)
Very high‐energy electron (VHEE) beams in radiation therapy; Treatment plan comparison between VHEE, VMAT, and PPBS (2017) (46)
Long-term outcomes after external beam irradiation and brachytherapy boost for base-of-tongue cancers. (2003) (46)
Comparison of respiratory surrogates for gated lung radiotherapy without internal fiducials (2006) (46)
Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). (2011) (45)
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting (2017) (45)
Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials (2019) (45)
Comparison of the comet assay and the oxygen microelectrode for measuring tumor oxygenation in head-and-neck cancer patients. (2003) (44)
Esophageal tolerance to high-dose stereotactic ablative radiotherapy. (2012) (44)
Results of a phase 2 study examining the effects of omitting elective neck irradiation to nodal levels IV and Vb in patients with N(0-1) nasopharyngeal carcinoma. (2013) (43)
Opportunities and challenges in the era of molecularly targeted agents and radiation therapy. (2013) (43)
New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting. (2008) (42)
Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. (2019) (42)
Prognostic significance of HPV and p16 status in patients with oropharyngeal cancer treated on a large international phase III trial. (2009) (42)
A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited‐stage small cell lung cancer in elderly patients versus younger patients (2018) (42)
CD44+ cells have cancer stem cell–like properties in nasopharyngeal carcinoma (2012) (41)
Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. (2011) (41)
Concurrent cetuximab versus platinum‐based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer (2015) (40)
Identification of Hypoxia-Regulated Proteins in Head and Neck Cancer by Proteomic and Tissue Array Profiling (2004) (39)
DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine. (1999) (39)
High retention and safety of percutaneously implanted endovascular embolization coils as fiducial markers for image-guided stereotactic ablative radiotherapy of pulmonary tumors. (2010) (39)
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. (2012) (39)
Age disparity in palliative radiation therapy among patients with advanced cancer. (2014) (38)
Comparison of treatment results between adult and juvenile nasopharyngeal carcinoma. (2009) (38)
Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years (2018) (37)
Hypoxic repression of pyruvate dehydrogenase activity is necessary for metabolic reprogramming and growth of model tumours (2016) (37)
Phase I Study of Tirapazamine Plus Cisplatin/Etoposide and Concurrent Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer (S0004) (2004) (37)
Tumor hypoxia is important in radiotherapy, but how should we measure it? (2002) (36)
Overview of Advances in Head and Neck Cancer. (2015) (36)
Treatment results of carcinoma in situ of the glottis: an analysis of 82 cases. (2000) (36)
Image Guided Stereotactic Radiosurgery for Lesions in Proximity to the Anterior Visual Pathways: A Preliminary Report (2002) (36)
Cost-effectiveness landscape analysis of treatments addressing xerostomia in patients receiving head and neck radiation therapy. (2013) (35)
Intensity‐modulated radiotherapy for locally advanced cancers of the larynx and hypopharynx (2011) (34)
The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. (2019) (32)
Emerging Treatment Paradigms in Radiation Oncology (2015) (32)
Discovery of recurrent structural variants in nasopharyngeal carcinoma (2014) (32)
Erratum: Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis (Cancer Research (June 1, 2006) 66 (5816-5827)) (2006) (31)
Image-based modeling of tumor shrinkage in head and neck radiation therapy. (2010) (30)
Intrafraction verification of gated RapidArc by using beam-level kilovoltage X-ray images. (2012) (30)
Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer (2011) (29)
Commutability of the Epstein-Barr Virus WHO International Standard across Two Quantitative PCR Methods (2014) (29)
Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504. (2018) (29)
Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy (1993) (28)
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. (2017) (28)
Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results‐Medicare analysis (2018) (27)
Extranodal nonorbital indolent lymphomas of the head and neck: relationship between tumor control and radiotherapy. (2004) (26)
Prognostic value of midtreatment FDG‐PET in oropharyngeal cancer (2016) (26)
Lung cancer in women: exploring sex differences in susceptibility, biology, and therapeutic response. (2006) (26)
A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. (2012) (26)
Identification of Doxorubicin as an Inhibitor of the IRE1α-XBP1 Axis of the Unfolded Protein Response (2016) (26)
In vivo 1H magnetic resonance spectroscopy of lactate in patients with stage IV head and neck squamous cell carcinoma. (2008) (25)
Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience. (2016) (25)
A Novel Aldehyde Dehydrogenase-3 Activator (Alda-89) Protects Submandibular Gland Function from Irradiation without Accelerating Tumor Growth (2013) (25)
Risk factors for clinician‐reported symptom clusters in patients with advanced head and neck cancer in a phase 3 randomized clinical trial: RTOG 0129 (2014) (25)
Salvage Treatment for Locally Recurrent Nasopharyngeal Carcinoma (NPC) (2014) (25)
Selection of external beam radiotherapy approaches for precise and accurate cancer treatment (2018) (25)
Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). (2016) (25)
A planned neck dissection is not necessary in all patients with N2-3 head-and-neck cancer after sequential chemoradiotherapy. (2012) (24)
Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer. (2017) (24)
Imaging features associated with disease progression after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer. (2014) (24)
Long-term results of radiation therapy oncology group 9903: a randomized phase 3 trial to assess the effect of erythropoietin on local-regional control in anemic patients treated with radiation therapy for squamous cell carcinoma of the head and neck. (2015) (23)
Estimating DNA repair by sequential evaluation of head and neck tumor radiation sensitivity using the comet assay. (2002) (23)
Advanced‐staged tonsillar squamous carcinoma: Organ preservation versus surgical management of the primary site (2006) (22)
Survival benefit for adjuvant radiation therapy in minor salivary gland cancers. (2015) (22)
Acridine Derivatives as Inhibitors of the IRE1α–XBP1 Pathway Are Cytotoxic to Human Multiple Myeloma (2016) (22)
Migration of implanted markers for image‐guided lung tumor stereotactic ablative radiotherapy (2013) (22)
Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy. (2019) (21)
International Recommendations on Re-irradiation by Intensity-modulated Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma. (2021) (21)
Pattern of recurrence of medulloblastoma after low-dose craniospinal radiotherapy. (1994) (21)
Quantitative and qualitative analysis of [18F]FDG and [18F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2016) (21)
Radiologic assessment of retropharyngeal node involvement in oropharyngeal carcinomas stratified by HPV status. (2013) (21)
Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. (2019) (21)
Indirect MR lymphangiography of the head and neck using conventional gadolinium contrast: a pilot study in humans. (2006) (20)
Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. (2013) (20)
Prognostic Value of p16 Status on the Development of a Complete Response in Involved Oropharynx Cancer Neck Nodes After Cisplatin-Based Chemoradiation: A Secondary Analysis of NRG Oncology RTOG 0129. (2016) (20)
Identifying and targeting hypoxia in head and neck cancer: a brief overview of current approaches. (2007) (19)
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis. (2021) (19)
Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non–Small Cell Lung Cancer: NRG Oncology RTOG 0839 (2017) (19)
Galectin-1 links tumor hypoxia and radiotherapy. (2014) (19)
Workshop Report for Cancer Research: Defining the Shades of Gy: Utilizing the Biological Consequences of Radiotherapy in the Development of New Treatment Approaches-Meeting Viewpoint. (2018) (18)
Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes (2018) (18)
Botulinum Toxin Confers Radioprotection in Murine Salivary Glands. (2013) (18)
Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer (2020) (18)
Smoking, age, nodal disease, T stage, p16 status, and risk of distant metastases in patients with squamous cell cancer of the oropharynx (2018) (17)
Palliative radiation before hospice: the long and the short of it. (2014) (16)
Head and Neck Cancer International Group (HNCIG) Consensus Guidelines for the delivery of postoperative radiation therapy in complex cutaneous squamous cell carcinoma of the head and neck (cSCCHN). (2020) (16)
Loss of the p53/p63 target PERP is an early event in oral carcinogenesis and correlates with higher rate of local relapse. (2013) (16)
β-Radioluminescence Imaging: A Comparative Evaluation with Cerenkov Luminescence Imaging (2015) (16)
Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504. (2019) (16)
p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC). (2013) (16)
Integrating biologically targeted therapy in head and neck squamous cell carcinomas. (2009) (16)
Survival After Definitive Chemoradiotherapy With Concurrent Cisplatin or Carboplatin for Head and Neck Cancer. (2019) (16)
Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer (2019) (16)
Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice? (2018) (15)
Safety of radiotherapy with concurrent and adjuvant MEDI4736 (durvalumab) in patients with locoregionally advanced head and neck cancer with a contraindication to cisplatin: NRG-HN004. (2019) (15)
A prospective study of electronic quality of life assessment using tablet devices during and after treatment of head and neck cancers. (2015) (15)
Long‐term outcomes of surgery followed by radiation therapy for minor salivary gland carcinomas (2013) (15)
Robust Estimation of Electron Density From Anatomic Magnetic Resonance Imaging of the Brain Using a Unifying Multi-Atlas Approach. (2017) (14)
Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy (2021) (14)
Reply to B. O'Sullivan et Al. (2015) (14)
Evaluation of ProExC as a Prognostic Marker in Oropharyngeal Squamous Cell Carcinomas (2012) (13)
Cost-Effectiveness of Nasopharyngeal Carcinoma Screening with Epstein-Barr Virus Polymerase Chain Reaction or Serology in High-Incidence Populations Worldwide. (2020) (13)
Prognostic model for distant metastasis in locally advanced nasopharyngeal carcinoma after concurrent chemoradiotherapy (2015) (13)
The effect of age on outcome in prospective, phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- chemotherapy in locally advanced (LA) head and neck cancer (HNC). (2015) (13)
CD 271 is a functional and targetable marker of tumor-initiating cells in head and neck squamous cell carcinoma (2016) (12)
Radiotherapy for nonadenoid cystic carcinomas of major salivary glands. (2013) (12)
Radiographic assessment of the sinuses in patients treated for nasopharyngeal carcinoma (2008) (12)
Lens dose in MLC-based IMRT treatments of the head and neck. (2004) (12)
Novel Aza-podophyllotoxin derivative induces oxidative phosphorylation and cell death via AMPK activation in triple-negative breast cancer (2020) (12)
Resection following concurrent chemotherapy and high-dose radiation for stage IIIA non-small cell lung cancer. (2020) (12)
Clinical Outcomes in Elderly Patients Treated for Oral Cavity Squamous Cell Carcinoma. (2017) (12)
A study to evaluate immunological response to PD-1 inhibition in squamous cell carcinoma of the head and neck (SCCHN) using novel PET imaging with [18F]F-AraG. (2018) (12)
Nasopharyngeal carcinoma (2019) (11)
Phase II study of chemoradiation plus bevacizumab (BV) for locally/regionally advanced nasopharyngeal carcinoma (NPC): Preliminary clinical results of RTOG 0615. (2011) (11)
The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal revisited (2017) (11)
Nonsurgical therapy for stages I and II non-small cell lung cancer. (2005) (11)
Lysosomal trafficking mediated by Arl8b and BORC promotes invasion of cancer cells that survive radiation (2020) (11)
A noninvasive approach for assessing tumor hypoxia in xenografts: developing a urinary marker for hypoxia. (2005) (11)
Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504 (2018) (10)
Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes, NRG Oncology/RTOG 9501-0234. (2015) (10)
Evaluation of a metal artifact reduction technique in tonsillar cancer delineation. (2012) (10)
Strategic plans to promote head and neck cancer translational research within the radiation therapy oncology group: a report from the translational research program. (2007) (10)
Evaluation of Oncology Trial Results Reporting Over a 10-Year Period (2021) (10)
Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer. (2021) (10)
Stereotactic Radiosurgery for Retreatment of Gross Perineural Invasion in Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck (2013) (10)
Higher incidence of head and neck cancers among Vietnamese American men in California (2010) (10)
Predictive classifier for intensive treatment of head and neck cancer (2020) (10)
Oral mucositis (OM) related morbidity and resource utilization in a prospective study of head and neck cancer (HNC) patients. (2006) (9)
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. (2021) (9)
Advances in pathogenesis and precision medicine for nasopharyngeal carcinoma (2021) (9)
Design and rationale of a prospective, multi‐institutional registry for patients with sinonasal malignancy (2016) (9)
Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes. (2017) (9)
Image-Guided Radiosurgery for the Spine and Pancreas (2000) (9)
Flexible radioluminescence imaging for FDG-guided surgery. (2016) (8)
Lambda-Carrageenan Enhances the Effects of Radiation Therapy in Cancer Treatment by Suppressing Cancer Cell Invasion and Metastasis through Racgap1 Inhibition (2019) (8)
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma. (2021) (8)
2192 The influence of overall radiation time (ORT) in patients treated with chemoradiotherapy for squamous cancer of the head and neck (1999) (7)
The use of plasma SELDI-TOF MS proteomic patterns for detection of head and neck squamous cell cancers (HNSCC) (2003) (7)
Molecular Imaging of Hypoxia-Inducible Factor 1α and von Hippel-Lindau Interaction in Mice (2008) (7)
104 candidate genes for the hypoxic tumor phenotype (1999) (7)
Nasopharyngeal and oropharyngeal carcinomas: target delineation, therapy delivery and stereotactic boost procedures with intensity-modulated/ image-guided radiation therapy. (2007) (7)
Cost-effectiveness of Screening for Nasopharyngeal Carcinoma among Asian American Men in the United States (2019) (7)
Rab27b contributes to radioresistance and exerts a paracrine effect via epiregulin in glioblastoma (2020) (6)
Thymic malignancies. (2010) (6)
Molecular imaging of hypoxia-inducible factor 1 alpha and von Hippel-Lindau interaction in mice. (2008) (6)
NCCN Non – Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (2010) (6)
Quantitative and qualitative analysis of [ 18 F]FDG and [ 18 F]FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2018) (6)
Title Proposal for the 8 th edition of the AJCC / UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy (2015) (6)
190 A medical knowledge based system for the selection of beam orientations in intensity-modulated radiation therapy (IMRT) (1999) (6)
Proton radiotherapy and treatment delay in head and neck squamous cell carcinoma (2019) (6)
Intensity-modulated and image-guided radiation therapy for head and neck cancers. (2011) (6)
Prolongation of definitive head and neck cancer radiotherapy: Survival impact and predisposing factors. (2020) (6)
Formation of an international intergroup to coordinate clinical trials in head and neck cancers: HNCIG. (2017) (6)
Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial (2004) (6)
Post-Radiation Metabolic Tumor Volume Predicts Outcome in Head-and-Neck Cancer (2011) (5)
Identification of cell types in multiplexed in situ images by combining protein expression and spatial information using CELESTA (2022) (5)
NRG-HN003: Phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiation therapy (IMRT), and MK-3475 (Pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC). (2019) (5)
Oral mucositis-related morbidity and resource utilization in a prospective study of head and neck cancer patients (2007) (5)
An International Consensus on the Design of Prospective Clinical–Translational Trials in Spatially Fractionated Radiation Therapy (2021) (5)
The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer. (2021) (5)
Quantitative PCR Methods WHO International Standard across Two Commutability of the Epstein-Barr Virus (2014) (4)
The microdissected gene expression landscape of nasopharyngeal cancer reveals vulnerabilities in FGF and noncanonical NF-κB signaling (2022) (4)
Effect of the extent of lymph node dissection on overall survival in patients treated for oral cavity squamous cell carcinoma. (2015) (4)
Nodal Metastasis Count and Oncologic Outcomes in Head and Neck Cancer: A Secondary Analysis of NRG/RTOG 9501, NRG/RTOG 0234, and EORTC 22931. (2022) (4)
Itensity modulated irradiation of nasopharynx carcinoma with inclusion of cervical and supraclavicular lymph nodes (1998) (4)
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer (2021) (4)
Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522. (2021) (4)
Radiotherapy for adenoid cystic carcinomas of the head and neck: clinical outcomes and patterns of failure (2011) (4)
Can Radiotherapy Quality Assurance (RT QA) improve nasopharyngeal cancer outcomes in low- and middle-income countries (LMICs) - Reporting the first phase of a prospective International Atomic Energy Agency (IAEA) study. (2021) (4)
Tumor Size is a Critical Determinant of Local Control in Single Fraction Stereotactic Radiotherapy of Pulmonary Tumors (2008) (4)
RADIATION THERAPY ONCOLOGY GROUP RTOG 0839 RANDOMIZED PHASE II STUDY OF PRE-OPERATIVE CHEMORADIOTHERAPY +/- PANITUMUMAB (IND #110152) FOLLOWED BY CONSOLIDATION CHEMOTHERAPY IN POTENTIALLY OPERABLE LOCALLY ADVANCED (STAGE IIIA, N2+) NON-SMALL CELL LUNG CANCER (2010) (4)
1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912 (2020) (4)
Volumetric-Modulated Arc Radiotherapy for Skull-Base and Non-Skull-Base Head and Neck Cancer: A Treatment Planning Comparison with Fixed Beam IMRT (2013) (3)
SU-E-T-492: The Dosimetric and Clinical Impact of the Metallic Dental Implants on Radiation Dose Distributions in IMRT Head and Neck Cancer Patients. (2012) (3)
Prognostic Signiﬁcance of p16 INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial (2010) (3)
The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma. (2012) (3)
Comment on: osteopontin as toxic marker. (2006) (3)
2428 : Retrospective and Prospective Studies of the Severity of Oral Mucositis (OM) in Intensity Modulated Radiation Therapy (IMRT) Compared to Conventional Radiation Therapy in Head and Neck Cancer (HNC) Patients (2006) (3)
Association of high Gli1 expression with poor survival in head and neck cancer patients treated with radiation therapy (RTOG 9003). (2010) (3)
Posttreatment FDG‐PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma (2022) (3)
Low-Dose Radiation Therapy (2 Gy x 2) in the Treatment of Non-Hodgkin Lymphoma of the Ocular Adnexa (2013) (3)
Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer. (2020) (3)
Modeling the Volumetric Change of Head and Neck Tumor in Response to Radiation Therapy (2007) (3)
HIF-α, a Gender Independent Transcription Factor (2003) (3)
Retraction Note: Lysyl oxidase is essential for hypoxia-induced metastasis (2020) (3)
Oropharynx: Epidemiology and Treatment Outcome (2009) (3)
On-board imaging validation of optically guided stereotactic radiosurgery positioning system for conventionally fractionated radiotherapy for paranasal sinus and skull base cancer. (2011) (3)
Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer. (2011) (3)
Radiation Resistance in Cancer Therapy: Meeting Summary and Research Opportunities Report of an NCI Workshop held September 1–3, 2010 (2011) (3)
A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1α–XBP1 Activation (2018) (3)
Candidate Genes for the Hypoxic Tumor Phenotype 1 (2000) (3)
Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations (2020) (3)
Cancer of the Larynx (1971) (3)
The Evidence Driven Dosimetric Constraints From Outcome Analysis of H&N Patients’ Data from NRG Oncology RTOG 0522 Trial (2017) (3)
Single fraction stereotactic radiosurgery (SFSR) for lung tumors - A phase I dose escalation trial. (2004) (3)
Influence of patient displacement and collimator and gantry angle misalignment on intensity modulated radiation therapy (1998) (2)
Comment on : Osteopontin as toxic marker. Authors' reply (2006) (2)
Evolutionary action score of TP53 analysis in pathologically high-risk HPV-negative head and neck cancer from a phase II clinical trial: NRG Oncology RTOG 0234. (2019) (2)
President Recent Work Title Quantitative and qualitative analysis of [ F-18 ] FDG and [ F-18 ] FAZA positron emission tomography of head and neck cancers and associations with HPV status and treatment outcome (2018) (2)
HIF-alpha, a gender independent transcription factor. (2003) (2)
Long-Term Update of a Phase II Study of Concurrent Chemoradiotherapy Using Radiation + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal Cancer (NPC): RTOG 0615 (2020) (2)
Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/RTOG 0129 and 0522 (2016) (2)
New Translational Possibilities for Microenvironmental Modulation of Radiosensitivity (2011) (2)
Hypoxia Imaging for Image-Guided Radiotherapy (2010) (2)
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial. (2023) (2)
Postoperative Observation Versus Radiotherapy for Pathologic N1 Oral Cavity Squamous Cell Carcinoma. (2021) (2)
Pilot study of loss of the p53/p63 target gene PERP at the surgical margin as a potential predictor of local relapse in head and neck squamous cell carcinoma (2020) (2)
Does Pre-treatment Metabolic Tumor Growth Rate (MTGR) Predict Progression in Lung Cancer? (2009) (2)
Preface (2018) (2)
Analysis of Migration of Implanted Markers for Image-Guided Lung Tumor Stereotactic Ablative Radiotherapy (2011) (2)
The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience. (2014) (2)
In Reply to Zoto Mustafayev and Ozyar. (2017) (2)
Focus on the Number of Radiation Oncology Trials or on Clinical Relevance-Reply. (2018) (2)
The Role of Tumor Hypoxia in Head and Neck Cancer Radiotherapy (2005) (2)
Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003 (2004) (2)
Safety evaluation of nivolumab (Nivo) concomitant with platinum-based chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504 (2018) (2)
2153 : Phase II Study to Assess the Efficacy of Gemcitabine Chemotherapy Followed by Stereotactic Body Radiotherapy (SBRT) in Patients With Locally Advanced Pancreatic Cancer (2006) (2)
Predicting overall survival (OS) and progression-free (PFS) for oropharynx cancers (OPC) in NRG Oncology RTOG0129/0522 with nomograms. (2016) (2)
Prognostic significance of interleukin-8 (IL-8) and hepatocyte growth factor (HGF) in patients with head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on a phase III trial. (2010) (2)
Radiographic Extranodal Extension in Human Papillomavirus-Associated Oropharyngeal Carcinoma: Can it Help Tailor Treatment? (2019) (2)
TU‐AB‐BRA‐10: Prognostic Value of Intra‐Radiation Treatment FDG‐PET and CT Imaging Features in Locally Advanced Head and Neck Cancer (2015) (2)
Individualizing treatment for patients with nasopharyngeal cancer (2015) (2)
Hypoxia, Angiogenesis, and Oral Cancer Metastasis (2009) (2)
Multicenter Clinical Cancer Research After COVID-19: A Perspective From NRG Oncology (2020) (2)
An Analysis of Patients with Clinically Localized High‐Risk Prostate Carcinoma (2000) (2)
18 FDG PET/CT prediction of treatment outcomes in patients with p16-positive, non-smoking associated, locoregionally advanced oropharyngeal cancer (LA-OPC) receiving deintensified therapy: Results from NRG-HN002. (2020) (2)
Acceler-dated fractionation: the end of the era of the large, "one size fits all" trial for locally advanced head and neck cancer. (2014) (1)
P-075 A comprehensive evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers (NSCLC) (2005) (1)
Integrating tumor and nodal imaging characteristics at baseline and mid-treatment CT scans to predict distant metastasis in oropharyngeal cancer treated with concurrent chemoradiotherapy (2019) (1)
Use of 3-D Printed Custom Oral Stents to Improve Positioning and Reproducibility for Patients Treated for Head and Neck Cancer (2018) (1)
Plasma human papillomavirus (HPV) DNA as a potential tool for tumor detection and monitoring response in HPV-related oropharyngeal carcinoma (OP). (2010) (1)
In Regard to Bossi et al. (2018) (1)
Abstract 1557: Tumor Galectin-1 mediates lung cancer growth and metastasis through immunoregulation of T-cell apoptosis (2011) (1)
Cisplatin or Carboplatin-Based Chemoradiation for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck: A Population-Based Comparison (2018) (1)
Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504. (2022) (1)
Proposal for the 8th edition of AJCC/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy (2016) (1)
Metabolic Tumor Burden Predicts for Disease Progression in Lung Cancer (2005) (1)
151 Influence of fractionation and time on local control of T1 and T2 glottic carcinoma (1996) (1)
Generalized Competing Event Regression to Stratify Head and Neck Cancer Patients: Secondary Analysis of NRG Oncology RTOG 9003, 0129, and 0522 (2017) (1)
Seamless phase II/III trial design with survival and PRO endpoints for treatment selection: Case study of RTOG 1216. (2013) (1)
Prognostic significance of plasma osteopontin in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation on TROG 02.02 phase III trial. (2011) (1)
Gene Expression in Nasopharyngeal Carcinoma by Laser Capture Microdissected Transcriptome Sequencing (2018) (1)
2106 An analysis of prognostic factors in patients with clinically localized high risk prostate cancer (1997) (1)
Abstract LB-180: Targeting galectin-1 in combination with radiation and immune checkpoint therapy in head and neck cancers (2017) (1)
P1-082: Metabolic tumor volume predicts disease progression and overall survival in lung cancer (2007) (1)
Predictor of effectiveness of treatment intensification on overall survival in head and neck cancer (HNC). (2018) (1)
Erratum: Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism (Proceedings of the National Academy of Sciences of the United States of America (2018) 115 (10756–10761) DOI: 10.1073/pnas.1808945115) (2018) (1)
Prognostic value of Epstein-Barr virus biomarkers for nasopharyngeal carcinoma staging and post-treatment surveillance (2021) (1)
Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma with Plasma Epstein-Barr Virus DNA (2018) (1)
An expanded study of the relationship between osteopontin, tumor pO2 and prognosis in head and neck squamous cell carcinomas (2005) (1)
P-94 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2021) (1)
12 LOX is essential for hypoxia-induced metastasis (2006) (1)
351 Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009 (2020) (1)
Evaluation of Intrafraction Motion in Head and Neck Cancer During Radiotherapy (2007) (1)
An assay of angiogenic protein expression in human umbilical vein endothelial cells (HUVECs) (2005) (1)
2790 : Auto Contour Mapping in CBCT for Adaptive Therapy Treatment Planning (2006) (1)
Molecular Signaling Pathways in Nasopharyngeal Cancer (2010) (1)
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic (2022) (1)
International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System (2022) (1)
Towards adaptive radiation therapy: Image-based tumor shrinkage modeling in head and neck cancer. (2009) (1)
Treatment Breaks During Definitive Head/Neck Radiotherapy: Survival Impact and Predisposing Factors (2020) (1)
SU-G-JeP2-02: A Unifying Multi-Atlas Approach to Electron Density Mapping Using Multi-Parametric MRI for Radiation Treatment Planning. (2016) (1)
Visualization of the unfolded protein response in primary tumors reveals unique microenvironments that reflect metabolic variations and predict for tumor growth (2010) (1)
2258 Spinal cord dose discrepancy in IMRT treated patients at Stanford revealed by Monte Carlo dose verification: Clinical summary (1999) (1)
Tumor hypoxia and metastasis in non-small cell lung cancers: M02-03 (2007) (1)
Radiation Resistance in Cancer Therapy: Meeting (2011) (1)
Oral Scientific SessionsFractionation Schedule and Risk of Local-Regional Failure for Patients treated on NRG Oncology RTOG 9003 and 0129 (2017) (1)
Risk stratification after recurrence of human papillomavirus (HPV)‐related and non‐HPV‐related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522 (2021) (1)
TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC). (2021) (1)
Survival from head and neck cancers based on socioeconomic status in Asians. (2010) (1)
National Effort to Re-Establish Heavy Ion Cancer Therapy in the United States (2022) (1)
B4-05: Development of a serum marker panel for early lung cancer detection and treatment response assessment using the proximity-ligation assay (PLA) (2007) (1)
Reflections on the 2021 Accreditation Council for Graduate Medical Education and American Board of Radiology Family and Medical Leave of Absence Policies: An Opportunity to Increase Structural Support for Physicians. (2023) (0)
A Nomogram for Outcomes after Chemoradiation for Non-HPV-Related Squamous Cell Carcinomas of the Head and Neck – A Pooled Analysis of NRG Oncology RTOG 0129 and 0522 (2019) (0)
Radiation Resistance in Cancer Therapy: meeting summary and research opportunities. Report of an NCI Workshop held September 1-3, 2010. (2011) (0)
Development of Laryngeal Cancer Nomograms From Pooled Data of Two Trials of Concurrent Chemoradiation: NRG Oncology RTOG 0129 and RTOG 0522 (2017) (0)
Esophageal Dose Tolerance in Stereotactic Body Radiotherapy (2010) (0)
ContRoVeRSY And ConSenSuS Meeting Viewpoint Workshop Report for Cancer Research : defining the Shades of Gy : utilizing the Biological Consequences of Radiotherapy in the development of new treatment Approaches (2018) (0)
2480 : Quantification of Motion for Different Thoracic Locations Using 4DCT: Implications for Radiation Treatment Planning (2006) (0)
Non-small cell lung cancer. (2008) (0)
Oropharynx : Epidemiology and Treatment Outcome 2 (2009) (0)
The role of Glial cell derived neurotrophic factor in head and neck cancer (2020) (0)
External irradiation plus 192IR interstitial implant compared with chemoradiation for squamous cell carcinoma of the base of tongue (1998) (0)
In Response to Dr. H. Christiansen et al. (2010) (0)
Feasibility of optimizing intensity‐modulated radiation therapy plans based on measured mucosal dose adjacent to dental fillings and toxicity outcomes (2018) (0)
Inhibition of pancreatic tumor growth and progression by a human monoclonal antibody specific for connective tissue growth factor (2005) (0)
Abstract B51: Targeting galectin-1 to improve therapeutic efficacy in head and neck cancers (2017) (0)
Prognostic and Predictive Signi fi cance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer (2012) (0)
Racial inequality with radiation oncology referral and treatment in metastatic colorectal cancer. (2013) (0)
De-escalating elective nodal irradiation for nasopharyngeal carcinoma. (2022) (0)
Clinical Management of Patients with Temporal Lobe Necrosis (2010) (0)
Evaluation of Radiation Therapy for NK-T-cell Lymphoma of the Head and Neck (2012) (0)
2766 : Dosimetric Impact by Temporal Changes of the PTV in Head in Neck Cancers (2006) (0)
Evaluation of a Knowledge-Guided Automated Treatment Planning Tool (2020) (0)
Abstract 1742: Evaluating the prognostic value of EGFR by p16/HPV status in patients with squamous cell carcinoma of the head and neck treated with concurrent chemoradiation (2010) (0)
Error in Figure 2. (2021) (0)
Habitat Evolution Imaging Biomarkers to Assess Early Response and Predict Treatment Outcomes in Oropharyngeal Cancer (2019) (0)
SP-016: New Markers of Metastases (2013) (0)
Multicenter Analysis of Clinical Outcomes of Sinonasal Mucosal Melanoma (2022) (0)
Can Temporal Lobe Necrosis be Prevented in Patients with Nasopharyngeal/Skull Base Tumors Undergoing a Stereotactic Radiosurgery Boost? A Dose Volume Analysis (2010) (0)
Abstract 62: Loss of PERP p53/p63 target gene may indicate tumorigenesis at the margin and local recurrence (2017) (0)
NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer. (2021) (0)
Incorrect Surnames in Byline. (2018) (0)
Abstract IA16: Midtreatment metabolic imaging as a biomarker of treatment response (2017) (0)
Low pre-operative absolute monocyte count to predict overall survival benefit for oral cavity squamous cell carcinoma. (2015) (0)
High Incidence of Larynx Cancers in Vietnamese Population in the Bay Area (2008) (0)
OC-016: Patient reported outcomes (PRO) of RTOG 9003 (2015) (0)
Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234 (2022) (0)
Evaluation of patterns of failure and subjective salivary function in patients treated with intensity modulated radiotherapy for head and neck squamous cell carcinomas. (2006) (0)
2184 A comparison between radiotherapy and surgery in the treatment of carcinoma in situ (CIS) of the vocal cord (1999) (0)
carcinoma Discovery of recurrent structural variants in nasopharyngeal Material (2013) (0)
SU‐FF‐J‐52: Dosimetric Impact by Temporal Changes of the GTV in Head and Neck Cancers (2006) (0)
Prognostic value of mid-treatment total lesion glycolysis in p16+ oropharyngeal cancer. (2015) (0)
Improving lung cancer screening rates among patients with head and neck cancer in a radiation oncology clinic (2022) (0)
Galectin-1 Orchestrates Immune Evasion in Head and Neck Cancer by Suppressing T Cell Recruitment to Tumors (2018) (0)
1032 Treatment of maxillary sinus carcinomas: A comparison of the 1983 and 1997 AJCC staging systems (1999) (0)
Moisture-seeking behavior may correlate with degree of radiation-induced xerostomia in mice (2016) (0)
Abstract 2068: A genome-wide siRNA screen reveals various modulators of the IRE1-XBP-1 signaling branch of the unfolded protein response (2011) (0)
Head and Neck Squamous Cell Cancer Response Assessment Biomarkers: Unplanned Analysis of the NRG Oncology RTOG 0522 PET Substudy (2017) (0)
Hypoxia and Radioresistance in Head and Neck Cancer (2014) (0)
The Clinical Impact of Hypoxia in Head and Neck Squamous Cell Carcinoma (2018) (0)
Prognostic Signi fi cance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02 . 02 Phase III Trial (2011) (0)
Final Report of NRG Oncology RTOG 0022: A Phase I/II Study of Conformal and Intensity. (2023) (0)
Feasibility of Optimizing IMRT Plans Based on Measured Mucosal Dose to Adjacent Metallic Dental Fillings for Head-and-Neck Cancer Patients (2012) (0)
Abstract 3374: Characterizing a new population of adult mouse submandibular gland stem cells (2012) (0)
Error in Figure 1. (2018) (0)
Multiplex Epstein-Barr Virus Genotyping PCR Detects High-Risk Variants in Plasma for Population-Level Nasopharyngeal Carcinoma Screening. (2021) (0)
A multidisciplinary approach to management in a patient with bilateral superior sulcus non-small-cell lung carcinoma. (2006) (0)
Targeting Lung Tumors in Image-Guided Stereotactic Ablative Radiotherapy using Pulmonary Interstitial Lymphography (2011) (0)
Aldehyde dehydrogenase 3A1 deficiency leads to mitochondrial dysfunction and impacts salivary gland stem cell self-renewal, differentiation and survival (2021) (0)
2760 : Analysis of Daily Set-Up Error by On-Board Imaging and Its Implications for PTV Margin Expansion (2006) (0)
Identification and Targeting Hypoxia in Head and Neck Cancer – A Brief Overview of Current Approaches (2008) (0)
83 : Molecular Imaging of HIF-1α and pVHL Interaction in Living Subjects Using Firefly Luciferase Complementation - Improvement Over the Renilla Luciferase System (2006) (0)
Expression and prognostic significance of tissue hypoxia markers in head and neck squamous cell carcinomas (HNSCC) (2005) (0)
Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma with Plasma Epstein Barr-Virus Plasma DNA or Serology in High-Incidence Populations Globally (2019) (0)
Abstract 3411: Biological subtypes of nasopharyngeal carcinoma by genomic profiling (2018) (0)
Expression of p16 as a prognostic marker in head and neck squamous cell carcinomas (HNSCC). (2005) (0)
Comparison of Multiplex Real-Time PCR and Droplet Digital PCR for Detection of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma. (2021) (0)
Prognostic Groups for p16-Positive Oropharyngeal Squamous Cell Cancer (p16-OPSCC) Treated With Chemoradiation Therapy (CRT) in NRG Oncology/RTOG 0129 and 0522 (2016) (0)
Hypoxia-related markers in the plasma of patients with advanced non-small cell lung cancer (NSCLC) and survival from chemotherapy: Southwest Oncology Group (SWOG) S0003. (2004) (0)
Introduction: Head and neck cancer. (2012) (0)
Feasibility of Pulmonary Interstitial Lymphography-guided Targeting in Stereotactic Ablative Radiation Therapy of Lung Tumors (2012) (0)
Hemoblobin levels in patients with advanced head and neck cancer do not correlate with tumor hypoxia (2000) (0)
SWOG 0222: A phase II study of tirapazamine (NSC-130181, TPZ)/cisplatin/etoposide (PE) and concurrent thoracic radiotherapy (TRT) for limited stage small-cell lung cancer (LSCLC) (2008) (0)
Outcomes of elderly patients treated for oral cavity squamous cell carcinoma. (2015) (0)
Post-Treatment FDG-PET/CT Hopkins Criteria Predict Locoregional Recurrence After Definitive Radiotherapy for Oropharyngeal Squamous Cell Carcinoma. (2021) (0)
Reply to A. Cmelak et al and B. Kalra et al. (2021) (0)
Definitive Radiotherapy for New Primary Tumors in the Lung: The Benefit of the Doubt (2010) (0)
TU-D-207B-03: Early Assessment of Response to Chemoradiotherapy Based On Textural Analysis of Pre and Mid-Treatment FDG-PET Image in Locally Advanced Head and Neck Cancer. (2016) (0)
Abstract 3202: Radiation increases invasive activity of breast cancer cells via altering lysosome exocytosis (2018) (0)
Title Prognostic significance of plasma osteopontin in patients with loco-regionally advanced head and neck squamous cell carcinoma treated on TROG 02 . 02 Phase III trial (2011) (0)
List of Contributors (2019) (0)
18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus–Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002 (2022) (0)
Changes in FDG-PET/CT Parameters on Serial Pre-radiotherapy Scans Predict Disease Progression and Survival in Patients with Non-small Cell Lung Cancer (2011) (0)
Abstract 2927: Papaverine and its novel derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism (2019) (0)
ABSTRACTS (1982) (0)
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. (2022) (0)
In Regard to Beadle and Anderson. (2018) (0)
Elevated osteopontin (OPN) plasma levels are highly prognostic in advanced non-small cell lung cancer (NSCLC): Analysis of SWOG S0003. (2006) (0)
Role of chemotherapy in 5 000 patients with head and neck cancer treated by curative surgery: a subgroup analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer (2020) (0)
Relationship Between Human Papillomavirus (HPV) Status, Epidermal Growth Factor Receptor (EGFR) and Phospho-EGFR (pEGFR) Expression in Head and Neck Squamous Cell Carcinoma (HNSCC) (2008) (0)
Cell cycle regulatory proteins and oral squamous cell carcinoma development (1998) (0)
Radiobiology of Lung Cancer (2018) (0)
In search for optimal induction chemotherapy for advanced nasopharyngeal cancer: Standard dosing of Docetaxel, Platinum, and 5-Fluorouracil (TPF) followed by chemoradiation (2023) (0)
Volume Doubling Times and Outcomes in Stereotactic Ablative Radiotherapy of Early-stage Non-small Cell Lung Cancer (2011) (0)
Immunotherapy of Head and Neck Cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 9-10, 2014, Bethesda, Maryland (2016) (0)
AXL Expression and Risk of Relapse in Non-Small Cell Lung Cancer (2012) (0)
Increased Galectin-1 Expression in Thymic Epithelial Tumors. (2019) (0)
Early Metabolic Response at Mid-Radiation Therapy FDG-PET Imaging Predicts Patterns of Treatment Failure in Locally Advanced Oropharyngeal Cancer (2018) (0)
Chemoradiation for nasopharyngeal carcinoma (NPC) with pilot hypoxia imaging with F18 misonidazole PET scanning. (2011) (0)
XBP-1 Is Essential for Tumor Angiogenesis in MEF Cells and in Human Fibrosarcoma HT 1080 Cells (2009) (0)
Single- and Multi-CT Robust Optimization Improves Robustness to Anatomic Changes in Head and Neck Cancer Patients Treated with Intensity-Modulated Proton Therapy (2018) (0)
Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy (2022) (0)
A discussion of the clinical use of advanced technologies in head and neck radiotherapy. (2007) (0)
A Unifying Multiatlas Approach to Electron Density Mapping Using Multiparametric Magnetic Resonance Imaging for Radiation Treatment Planning (2016) (0)
Radiologic Assessment of Lymph Node Involvement in HPV/p16+ Oropharyngeal Cancers (2012) (0)
Comments on the Publication by Corkum et al on “Does 5 + 5 mm Equal Better Radiation Treatment Plans in Head and Neck Cancers?” (2020) (0)
JUPITER‐02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps (2021) (0)
PET/CT in lung cancer Mid-radiotherapy PET/CT for prognostication and detection of early progression in patients with stage III non-small cell lung cancer Radiotherapy and Oncology (2018) (0)
255 INVITED Targeting Galectin-1, a Hypoxia Induced Protein, in Non-Small Cell Lung Cancers (2011) (0)
The Unique Microenvironments of Spontaneous Tumors Differentially Sensitize Them to Radiation (2009) (0)
Effect of Glial cell derived neurotrophic factor (GDNF) on migration and survival of head and neck squamous cell carcinoma (HNSCC) (2016) (0)
The Role of Department Chair (2021) (0)
Neurotrophic factor promotes stem cell involved salivary gland regeneration post radiotherapy. (2015) (0)
Abstract 848: Galectin-1 mediates radiation-related lymphopenia in non-small cell lung cancer and attenuates tumor radiation response (2014) (0)
Abstract 571: Osteopontin (OPN) inhibition as a novel therapeutic strategy in targeting non-small cell lung cancer (NSCLC) (2011) (0)
Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839. (2016) (0)
Survey of the Adoption of the UICC/AJCC 8th Edition TNM for Head and Neck Cancer: The User’s Initial Experience (2019) (0)
Abstract PO-066: Relationship between KEAP1/NFE2L2 pathway activation and radiation resistance in oral cavity cancer (2021) (0)
American Radium Society 92nd Annual Meeting (2010) (0)
Stereotactic Ablative Radiotherapy for Previously Irradiated Lung Tumors (2011) (0)
Reply to P. Bossi et al (2012) (0)
Abstract PO-048: VISTA immune-checkpoint blunts radiotherapy induced anti-tumor immune response (2021) (0)
Pulmonary Interstitial Lymphography and Patterns of Recurrence after Stereotactic Ablative Radiation Therapy(SABR) of Lung Tumors (2018) (0)
Adipophilin: a novel hypoxia regulated gene (2002) (0)
Mid-radiation Therapy PET/CT for Prognostication and Detection of Early Progression in Patients With Stage III Non–small Cell Lung Cancer (2017) (0)
Human-Level Comparable Control Volumes Mapping With an Unsupervised-Learning Model for CT-Guided Radiotherapy. (2021) (0)
Abstract 4068: Galectin-1 intensifies immunosuppression in head and neck cancer by boosting myeloid-derived suppressive cell (MDSC) expansion (2018) (0)
oxia in Models of Lung Cancer : Implications for R geted Therapeutics (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Quynh-thu X. Le?

Quynh-thu X. Le is affiliated with the following schools:

University of California, San Diego
Stanford University

Quynh-thu X. Le's Academic­Influence.com Rankings

Quynh-thu X. Le's Degrees

Why Is Quynh-thu X. Le Influential?

Quynh-thu X. Le's Published Works

Published Works

What Schools Are Affiliated With Quynh-thu X. Le?

Quynh-thu X. Le's AcademicInfluence.com Rankings